Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. T…
Biotechnology
US, Waltham [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Apellis Pharmaceuticals, Inc. (APLS) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 14,227.21 | 931.44 | 144.78 | 373.02 | 19.38 | 0.00 | 24.3787 | -0.78 | -0.9302 | -21.6264 | -0.08 | -0.08 | 6.8286 | - - | ||
| Maximum | - - | - - | - - | 444,129.00 | 65,349.00 | 25,407.00 | 99,050.00 | 5,305.00 | 0.02 | 1,336.3467 | 6.70 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -6,783.00 | -56,335.00 | -2,077.00 | 0.00 | -164.8536 | -57.22 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0007 | - - | ||
| Madrigal Pharmaceuticals, Inc. MDGL | 329.24 | 12.15 3.83% | 421 vs. 376 | 7,180.00 | 0.00 | -147.00 | -149.00 | -1,483.00 | -7.3800 | -8.6674 | 0.0000 | 0.0000 | 0.0000 | -0.1734 | -0.1363 | 9.2623 | 21.00 | ||
| Akero Therapeutics, Inc. AKRO | 31.20 | 0.57 1.84% | 522 vs. 551 | 2,177.00 | 0.00 | -53.00 | -35.00 | -627.00 | -0.9000 | -6.6902 | 0.0000 | 0.0000 | 0.0000 | -0.0630 | -0.0585 | 29.8643 | 69.00 | ||
| Prometheus Biosciences, Inc. RXDX | 199.92 | 0.18 0.09% | 1,787 vs. 1,217 | 9,558.00 | 1.00 | -40.00 | -40.00 | -371.00 | -0.8600 | -31.1524 | 0.0000 | 1.0000 | -36.9919 | -0.0586 | -0.0539 | 36.9012 | 47.00 | ||
| Cerevel Therapeutics Holdings, Inc. CERE | 44.96 | 0.33 0.74% | 15,033 vs. 2,056 | 8,191.00 | 0.00 | -131.00 | -119.00 | -1,532.00 | -0.7300 | -14.5661 | 0.0000 | 0.0000 | 0.0000 | -0.2337 | -0.1170 | 10.1215 | 182.00 | ||
| Blueprint Medicines Corporation BPMC | 96.62 | 1.81 1.91% | 741 vs. 620 | 6,137.00 | 96.00 | 89.00 | -102.00 | -2,250.00 | 1.4500 | 16.6530 | 0.0000 | 0.9168 | 0.9274 | 0.2869 | 0.0858 | 3.4266 | 63.00 | ||
| Apellis Pharmaceuticals, Inc. APLS | 27.75 | 0.26 0.95% | 1,488 vs. 2,868 | 3,451.00 | 172.00 | -66.00 | -133.00 | -2,903.00 | -0.5400 | -27.6326 | 0.0000 | 0.8802 | -0.3855 | -0.2491 | -0.0798 | 2.7985 | 124.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.